Profile
Jeff S.
Hartness currently works at Corganics LP, as Director from 2022, Bryn Pharma LLC, as Director from 2022, and Apogee Therapeutics, Inc., as Chief Commercial Officer from 2024.
Mr. Hartness also formerly worked at Bausch Health Cos., Inc., as Executive VP-Generics and Government Affairs.
Mr. Hartness received his undergraduate degree from Hanover College.
Jeff Hartness active positions
| Companies | Position | Start |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Corporate Officer/Principal | 09/09/2024 |
Corganics LP
Corganics LP Medical DistributorsDistribution Services Manufactures and distributes natural topical pain analgesic cream | Director/Board Member | 23/02/2022 |
Bryn Pharma LLC
Bryn Pharma LLC Medical SpecialtiesHealth Technology Develops bi-dose intranasal devices for patients with anaphylaxis | Director/Board Member | 13/12/2022 |
Former positions of Jeff Hartness
| Companies | Position | End |
|---|---|---|
| BAUSCH HEALTH COMPANIES INC. | General Counsel | - |
Training of Jeff Hartness
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Hanover College
Hanover College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bausch Health Cos., Inc.
Bausch Health Cos., Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Corganics LP
Corganics LP Medical DistributorsDistribution Services Manufactures and distributes natural topical pain analgesic cream | Distribution Services |
Bryn Pharma LLC
Bryn Pharma LLC Medical SpecialtiesHealth Technology Develops bi-dose intranasal devices for patients with anaphylaxis | Health Technology |
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops therapies for immunological and inflammatory disorders | Health Technology |
- Stock Market
- Insiders
- Jeff Hartness
















